Affordable Access

deepdyve-link
Publisher Website

Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids.

Authors
  • Kuramoto, Kenta1
  • Wang, Nan1, 2
  • Fan, Yuying1, 3
  • Zhang, Weiran1
  • Schoenen, Frank J4
  • Frankowski, Kevin J5
  • Marugan, Juan6
  • Zhou, Yifa3
  • Huang, Sui1
  • He, Congcong1
  • 1 a Department of Cell and Molecular Biology , Feinberg School of Medicine, Northwestern University , Chicago , IL , USA.
  • 2 b Key Laboratory of Industrial Microbiology, Ministry of Education and Tianjin City, College of Biotechnology, Tianjin University of Science and Technology , Tianjin , China. , (China)
  • 3 c School of Life Sciences, Northeast Normal University , Changchun , Jilin , China. , (China)
  • 4 d Higuchi Biosciences Center, University of Kansas , Lawrence , KS , USA.
  • 5 e UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.
  • 6 f Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda , MD , USA.
Type
Published Article
Journal
Autophagy
Publisher
Landes Bioscience
Publication Date
Sep 01, 2016
Volume
12
Issue
9
Pages
1460–1471
Identifiers
DOI: 10.1080/15548627.2016.1187367
PMID: 27305347
Source
Medline
Keywords
License
Unknown

Abstract

Cannabinoids and related drugs generate profound behavioral effects (such as analgesic effects) through activating CNR1 (cannabinoid receptor 1 [brain]). However, repeated cannabinoid administration triggers lysosomal degradation of the receptor and rapid development of drug tolerance, limiting the medical use of marijuana in chronic diseases. The pathogenic mechanisms of cannabinoid tolerance are not fully understood, and little is known about its prevention. Here we show that a protein involved in macroautophagy/autophagy (a conserved lysosomal degradation pathway), BECN2 (beclin 2), mediates cannabinoid tolerance by preventing CNR1 recycling and resensitization after prolonged agonist exposure, and deletion of Becn2 rescues CNR1 activity in mouse brain and conveys resistance to analgesic tolerance to chronic cannabinoids. To target BECN2 therapeutically, we established a competitive recruitment model of BECN2 and identified novel synthetic, natural or physiological stimuli of autophagy that sequester BECN2 from its binding with GPRASP1, a receptor protein for CNR1 degradation. Co-administration of these autophagy inducers effectively restores the level and signaling of brain CNR1 and protects mice from developing tolerance to repeated cannabinoid usage. Overall, our findings demonstrate the functional link among autophagy, receptor signaling and animal behavior regulated by psychoactive drugs, and develop a new strategy to prevent tolerance and improve medical efficacy of cannabinoids by modulating the BECN2 interactome and autophagy activity.

Report this publication

Statistics

Seen <100 times